Home » Stocks » KRBP

Kiromic BioPharma, Inc. (KRBP)

Stock Price: $8.75 USD -0.48 (-5.20%)
Updated Jan 25, 2021 3:15 PM EST - Market open
Market Cap 67.61M
Revenue (ttm) n/a
Net Income (ttm) -16.28M
Shares Out 7.33M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $8.75
Previous Close $9.23
Change ($) -0.48
Change (%) -5.20%
Day's Open 9.50
Day's Range 8.75 - 9.55
Day's Volume 17,387
52-Week Range 8.11 - 11.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 days ago

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platfo...

Business Wire - 2 weeks ago

HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a t...

Business Wire - 1 month ago

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network pla...

Business Wire - 1 month ago

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform ...

Business Wire - 3 months ago

HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with ...

About KRBP

Kiromic BioPharma, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare p... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
CEO
Dr. Maurizio Chiriva Internati Ph.D.
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
KRBP
Full Company Profile

Financial Performance

Financial Statements